PXMP2
gene geneOn this page
Also known as PMP22MPV17L3
Summary
PXMP2 (peroxisomal membrane protein 2, HGNC:9716) is a protein-coding gene on chromosome 12q24.33, encoding Peroxisomal membrane protein 2 (Q9NR77). Seems to be involved in pore-forming activity and may contribute to the unspecific permeability of the peroxisomal membrane.
Located in peroxisomal membrane. Part of protein-containing complex.
Source: NCBI Gene 5827 — RefSeq curated summary.
At a glance
- GWAS associations: 4
- Clinical variants (ClinVar): 40 total — 1 pathogenic
- MANE Select transcript:
NM_018663
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:9716 |
| Approved symbol | PXMP2 |
| Name | peroxisomal membrane protein 2 |
| Location | 12q24.33 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | PMP22, MPV17L3 |
| Ensembl gene | ENSG00000176894 |
| Ensembl biotype | protein_coding |
| OMIM | 617399 |
| Entrez | 5827 |
Gene structure
Transcript identifiers
Ensembl transcripts: 9 — 8 protein_coding, 1 nonsense_mediated_decay
ENST00000317479, ENST00000428960, ENST00000454379, ENST00000539093, ENST00000543589, ENST00000856532, ENST00000856533, ENST00000856534, ENST00000856535
RefSeq mRNA: 1 — MANE Select: NM_018663
NM_018663
CCDS: CCDS9279
Canonical transcript exons
ENST00000317479 — 5 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001293459 | 132687587 | 132687792 |
| ENSE00002230284 | 132704619 | 132704985 |
| ENSE00003467180 | 132701250 | 132701369 |
| ENSE00003468031 | 132690263 | 132690376 |
| ENSE00003715973 | 132695884 | 132696046 |
Expression profiles
Bgee: expression breadth ubiquitous, 134 present calls, max score 98.68.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.0443 / max 167.0632, expressed in 1767 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 128828 | 18.0443 | 1767 |
Top tissues by expression
134 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| right lobe of liver | UBERON:0001114 | 98.68 | gold quality |
| liver | UBERON:0002107 | 98.16 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 97.90 | gold quality |
| body of stomach | UBERON:0001161 | 95.69 | gold quality |
| apex of heart | UBERON:0002098 | 95.09 | gold quality |
| duodenum | UBERON:0002114 | 95.09 | gold quality |
| adult mammalian kidney | UBERON:0000082 | 94.96 | gold quality |
| fundus of stomach | UBERON:0001160 | 94.62 | gold quality |
| heart left ventricle | UBERON:0002084 | 94.49 | gold quality |
| stomach | UBERON:0000945 | 94.45 | gold quality |
| ventricular zone | UBERON:0003053 | 93.63 | gold quality |
| transverse colon | UBERON:0001157 | 93.60 | gold quality |
| ganglionic eminence | UBERON:0004023 | 92.56 | gold quality |
| kidney | UBERON:0002113 | 92.54 | gold quality |
| heart | UBERON:0000948 | 92.52 | gold quality |
| gastrocnemius | UBERON:0001388 | 91.87 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 91.75 | gold quality |
| rectum | UBERON:0001052 | 91.72 | gold quality |
| body of pancreas | UBERON:0001150 | 91.69 | gold quality |
| small intestine | UBERON:0002108 | 91.57 | gold quality |
| muscle of leg | UBERON:0001383 | 91.51 | gold quality |
| right atrium auricular region | UBERON:0006631 | 91.27 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 91.15 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 90.47 | gold quality |
| thoracic aorta | UBERON:0001515 | 90.41 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 90.37 | gold quality |
| ascending aorta | UBERON:0001496 | 90.33 | gold quality |
| intestine | UBERON:0000160 | 90.17 | gold quality |
| colon | UBERON:0001155 | 89.80 | gold quality |
| cortex of kidney | UBERON:0001225 | 89.73 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 8.69 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
10 targeting PXMP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-153-5P | 99.89 | 73.86 | 6317 |
| HSA-MIR-4756-3P | 99.62 | 66.30 | 1319 |
| HSA-MIR-20A-3P | 99.44 | 69.10 | 1575 |
| HSA-MIR-7151-5P | 99.37 | 67.82 | 613 |
| HSA-MIR-6719-3P | 99.29 | 67.78 | 1387 |
| HSA-MIR-6804-3P | 98.72 | 64.82 | 852 |
| HSA-MIR-3622A-3P | 97.06 | 66.43 | 1000 |
| HSA-MIR-4793-5P | 96.88 | 65.90 | 872 |
| HSA-MIR-3622B-3P | 96.82 | 66.36 | 988 |
| HSA-MIR-152-5P | 96.42 | 66.59 | 960 |
Literature-anchored findings (GeneRIF, showing 1)
- Authors provide evidence that PXMP2 is not essential for H2O2 permeation across the peroxisomal membrane, neither in control cells nor in cells lacking PEX11B, a peroxisomal membrane-shaping protein whose yeast homologue facilitates the permeation of molecules up to 400Da. (PMID:31129117)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | pxmp2 | ENSDARG00000003144 |
| mus_musculus | Pxmp2 | ENSMUSG00000029499 |
| rattus_norvegicus | Pxmp2 | ENSRNOG00000037446 |
| drosophila_melanogaster | CG7970 | FBGN0035252 |
Paralogs (3): MPV17 (ENSG00000115204), MPV17L (ENSG00000156968), MPV17L2 (ENSG00000254858)
Protein
Protein identifiers
Peroxisomal membrane protein 2 — Q9NR77 (reviewed: Q9NR77)
Alternative names: 22 kDa peroxisomal membrane protein
All UniProt accessions (5): A0A087X249, Q9NR77, F5GXM0, F5GZF7, F5H4N4
UniProt curated annotations — full annotation on UniProt →
Function. Seems to be involved in pore-forming activity and may contribute to the unspecific permeability of the peroxisomal membrane.
Subunit / interactions. Interacts with PEX19 and SIVA1.
Subcellular location. Peroxisome membrane.
Similarity. Belongs to the peroxisomal membrane protein PXMP2/4 family.
RefSeq proteins (1): NP_061133* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR007248 | Mpv17_PMP22 | Family |
Pfam: PF04117
UniProt features (9 total): topological domain 4, transmembrane region 4, chain 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9NR77-F1 | 85.58 | 0.51 |
Function
Pathways and Gene Ontology
Reactome pathways
2 pathways
| ID | Pathway |
|---|---|
| R-HSA-389661 | Glyoxylate metabolism and glycine degradation |
| R-HSA-9603798 | Class I peroxisomal membrane protein import |
MSigDB gene sets: 757 (showing top):
WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN, TGGTGCT_MIR29A_MIR29B_MIR29C, chr17p12, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, BENPORATH_ES_WITH_H3K27ME3, CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN, YAGI_AML_WITH_INV_16_TRANSLOCATION, KAAB_FAILED_HEART_ATRIUM_DN, GNF2_GSTM1, GNF2_HPN, ASTON_MAJOR_DEPRESSIVE_DISORDER_DN, SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER, GOBP_NEUROGENESIS, KANNAN_TP53_TARGETS_DN, TOMLINS_PROSTATE_CANCER_DN
GO Biological Process (0):
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (6): cytoplasm (GO:0005737), peroxisomal membrane (GO:0005778), cytosol (GO:0005829), membrane (GO:0016020), protein-containing complex (GO:0032991), peroxisome (GO:0005777)
Reactome top-level categories
Rollup of top-2 pathways:
| Category | Pathways |
|---|---|
| Metabolism of amino acids and derivatives | 1 |
| Protein localization | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 3 |
| binding | 1 |
| intracellular anatomical structure | 1 |
| peroxisome | 1 |
| microbody membrane | 1 |
| cytoplasm | 1 |
| cellular_component | 1 |
| microbody | 1 |
Protein interactions and networks
STRING
1072 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| PXMP2 | PEX11A | O75192 | 653 |
| PXMP2 | PEX11B | O96011 | 651 |
| PXMP2 | PEX16 | Q9Y5Y5 | 597 |
| PXMP2 | PXMP4 | Q9Y6I8 | 571 |
| PXMP2 | PEX11G | Q96HA9 | 549 |
| PXMP2 | DAO | P14920 | 532 |
| PXMP2 | ACBD5 | Q5T8D3 | 501 |
| PXMP2 | SLC25A17 | O43808 | 489 |
| PXMP2 | ALDH3A2 | P51648 | 470 |
| PXMP2 | PEX13 | Q92968 | 468 |
| PXMP2 | SNX15 | Q9NRS6 | 466 |
| PXMP2 | NUDT12 | Q9BQG2 | 459 |
| PXMP2 | ABCD1 | P33897 | 458 |
| PXMP2 | H3BMD7 | H3BMD7 | 453 |
| PXMP2 | HAO1 | Q9UJM8 | 448 |
IntAct
73 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| IFT70B | IFT56 | psi-mi:“MI:0914”(association) | 0.790 |
| PXMP2 | PEX19 | psi-mi:“MI:0915”(physical association) | 0.770 |
| PXMP2 | PEX19 | psi-mi:“MI:0407”(direct interaction) | 0.770 |
| TRDN | TMEM223 | psi-mi:“MI:0914”(association) | 0.640 |
| MME | TMEM223 | psi-mi:“MI:0914”(association) | 0.530 |
| SLC15A1 | METTL15 | psi-mi:“MI:0914”(association) | 0.530 |
| SLC39A9 | B4GALT5 | psi-mi:“MI:0914”(association) | 0.530 |
| PEX19 | FAM20B | psi-mi:“MI:0914”(association) | 0.530 |
| SLC22A16 | APBA3 | psi-mi:“MI:0914”(association) | 0.530 |
| PEX19 | MYO1D | psi-mi:“MI:0914”(association) | 0.530 |
| PXMP2 | SIVA1 | psi-mi:“MI:0915”(physical association) | 0.510 |
| SIVA1 | PXMP2 | psi-mi:“MI:0915”(physical association) | 0.510 |
| GPC1 | SNAP23 | psi-mi:“MI:0915”(physical association) | 0.400 |
| GPC1 | GANAB | psi-mi:“MI:0915”(physical association) | 0.400 |
| ERGIC3 | TMEM223 | psi-mi:“MI:0914”(association) | 0.350 |
| TMCO3 | POTEF | psi-mi:“MI:0914”(association) | 0.350 |
| SLC18A1 | LIMK2 | psi-mi:“MI:0914”(association) | 0.350 |
| FPR2 | GPR89A | psi-mi:“MI:0914”(association) | 0.350 |
| SLC5A8 | GPR89A | psi-mi:“MI:0914”(association) | 0.350 |
| SLC6A15 | GPR89A | psi-mi:“MI:0914”(association) | 0.350 |
| SLC1A1 | TNFRSF10B | psi-mi:“MI:0914”(association) | 0.350 |
| SLC22A16 | AGPAT2 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (301): KRT40 (Two-hybrid), PXMP2 (Affinity Capture-MS), PXMP2 (Affinity Capture-MS), PXMP2 (Affinity Capture-MS), PXMP2 (Affinity Capture-MS), PXMP2 (Affinity Capture-MS), PXMP2 (Affinity Capture-MS), PXMP2 (Affinity Capture-MS), PXMP2 (Affinity Capture-MS), PXMP2 (Affinity Capture-MS), PXMP2 (Affinity Capture-MS), PXMP2 (Affinity Capture-MS), PXMP2 (Affinity Capture-MS), PXMP2 (Affinity Capture-MS), PXMP2 (Affinity Capture-MS)
ESM2 similar proteins: A6ZV78, A7A285, A8E7G5, B0G159, B3LUQ6, B5VI70, O14142, P0CQ38, P0CQ39, P38857, P40464, P42925, P43617, P53257, Q06563, Q07066, Q10244, Q2KIK2, Q2KIY1, Q2QL34, Q3ZCG2, Q4P9K6, Q4WDZ0, Q54FR4, Q54GD8, Q54XX9, Q54ZX5, Q59Q43, Q5EA43, Q5RD16, Q60SZ2, Q68F62, Q6BMY0, Q6CAW5, Q6CIY7, Q6FXJ3, Q754F0, Q7YWV6, Q86I81, Q925N2
Diamond homologs: O14142, P0CQ38, P0CQ39, P19258, P39210, P42925, Q06563, Q07066, Q08743, Q10244, Q2KIN6, Q2KIY1, Q2TXA2, Q4IPX8, Q4P9K6, Q4WDZ0, Q54XX9, Q54ZX5, Q59Q43, Q5BK62, Q5TZ51, Q60SZ2, Q66GV0, Q6BMY0, Q6CAW5, Q6CIY7, Q6FXJ3, Q754F0, Q7SCY7, Q9NR77, Q54FR4, Q54GD8, Q6DGV7, Q2QL34, Q567V2, Q8VIK2, A5D787, Q6DIY8, Q7YWV6, Q99MS3
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 82 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| R-HSA-425393 | 6 | 15.0× | 2e-04 |
| SLC-mediated transmembrane transport | 10 | 11.4× | 3e-06 |
| Transport of small molecules | 13 | 6.3× | 9e-06 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| sodium ion transport | 5 | 17.4× | 3e-03 |
| monoatomic ion transport | 6 | 12.0× | 3e-03 |
| intracellular calcium ion homeostasis | 6 | 11.2× | 3e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
40 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 1 |
| Likely pathogenic | 0 |
| Uncertain significance | 25 |
| Likely benign | 3 |
| Benign | 1 |
Top pathogenic / likely-pathogenic (1)
| Variant ID | HGVS | Classification |
|---|---|---|
| 638102 | GRCh37/hg19 12q24.33(chr12:131363916-133777645)x3 | Pathogenic |
SpliceAI
1558 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 12:132687792:GGTG:G | donor_loss | 1.0000 |
| 12:132687793:GTGAG:G | donor_loss | 1.0000 |
| 12:132690261:A:AG | acceptor_gain | 1.0000 |
| 12:132690262:G:GG | acceptor_gain | 1.0000 |
| 12:132690262:GTGGC:G | acceptor_gain | 1.0000 |
| 12:132690375:GG:G | donor_gain | 1.0000 |
| 12:132690376:GG:G | donor_gain | 1.0000 |
| 12:132690377:G:GG | donor_gain | 1.0000 |
| 12:132690377:G:T | donor_loss | 1.0000 |
| 12:132690378:T:A | donor_loss | 1.0000 |
| 12:132701244:TTGCA:T | acceptor_loss | 1.0000 |
| 12:132701245:T:TA | acceptor_gain | 1.0000 |
| 12:132701245:TGCAG:T | acceptor_loss | 1.0000 |
| 12:132701246:GCA:G | acceptor_loss | 1.0000 |
| 12:132701247:CA:C | acceptor_loss | 1.0000 |
| 12:132701247:CAG:C | acceptor_loss | 1.0000 |
| 12:132701248:A:AC | acceptor_loss | 1.0000 |
| 12:132701248:A:AG | acceptor_gain | 1.0000 |
| 12:132701248:AG:A | acceptor_gain | 1.0000 |
| 12:132701248:AGG:A | acceptor_gain | 1.0000 |
| 12:132701248:AGGG:A | acceptor_gain | 1.0000 |
| 12:132701249:G:GT | acceptor_gain | 1.0000 |
| 12:132701249:GG:G | acceptor_gain | 1.0000 |
| 12:132701249:GGG:G | acceptor_gain | 1.0000 |
| 12:132701249:GGGG:G | acceptor_gain | 1.0000 |
| 12:132701366:GAAG:G | donor_gain | 1.0000 |
| 12:132701368:AGG:A | donor_loss | 1.0000 |
| 12:132701369:GGTG:G | donor_loss | 1.0000 |
| 12:132701370:G:GA | donor_loss | 1.0000 |
| 12:132701370:GTGAG:G | donor_loss | 1.0000 |
AlphaMissense
1258 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 12:132701348:C:A | N166K | 0.986 |
| 12:132701348:C:G | N166K | 0.986 |
| 12:132690265:G:A | G42D | 0.985 |
| 12:132690376:G:A | G79E | 0.985 |
| 12:132701359:T:A | V170D | 0.985 |
| 12:132690264:G:C | G42R | 0.979 |
| 12:132687791:A:C | S41R | 0.978 |
| 12:132690263:T:A | S41R | 0.978 |
| 12:132690263:T:G | S41R | 0.978 |
| 12:132695897:G:T | G84W | 0.978 |
| 12:132701344:T:A | I165N | 0.978 |
| 12:132695906:A:C | S87R | 0.977 |
| 12:132695908:T:A | S87R | 0.977 |
| 12:132695908:T:G | S87R | 0.977 |
| 12:132701315:C:A | N155K | 0.977 |
| 12:132701315:C:G | N155K | 0.977 |
| 12:132690375:G:T | G79W | 0.976 |
| 12:132701316:T:A | W156R | 0.976 |
| 12:132701316:T:C | W156R | 0.976 |
| 12:132701327:G:C | W159C | 0.976 |
| 12:132701327:G:T | W159C | 0.976 |
| 12:132695898:G:A | G84E | 0.975 |
| 12:132696020:T:C | F125L | 0.974 |
| 12:132696022:C:A | F125L | 0.974 |
| 12:132696022:C:G | F125L | 0.974 |
| 12:132687782:G:C | A38P | 0.972 |
| 12:132701325:T:A | W159R | 0.972 |
| 12:132701325:T:C | W159R | 0.972 |
| 12:132690367:C:A | A76D | 0.970 |
| 12:132704639:C:A | N180K | 0.969 |
dbSNP variants (sampled 300 via entrez): RS1000230189 (12:132705482 G>A), RS1000334479 (12:132699879 G>A,T), RS1000541182 (12:132691866 A>G), RS1000593110 (12:132685961 C>T), RS10007 (12:132704876 G>A), RS1000795616 (12:132705447 C>T), RS1000958627 (12:132702206 A>G), RS1001129293 (12:132699687 G>A), RS1001136456 (12:132696339 C>T), RS1001286705 (12:132704955 A>T), RS1001361950 (12:132691207 A>G), RS1001410417 (12:132699815 A>G), RS1001430551 (12:132685651 A>G), RS1001430822 (12:132687642 G>A,C,T), RS1001476439 (12:132687494 A>G)
Disease associations
OMIM: gene MIM:617399 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
4 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST90002387_131 | Immature fraction of reticulocytes | 5.000000e-12 |
| GCST90002390_181 | Mean corpuscular hemoglobin | 7.000000e-13 |
| GCST90002396_544 | Mean reticulocyte volume | 2.000000e-10 |
| GCST90002397_53 | Mean spheric corpuscular volume | 3.000000e-11 |
EFO canonical traits (2, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004527 | mean corpuscular hemoglobin |
| EFO:0010701 | mean reticulocyte volume |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
41 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Aflatoxin B1 | affects expression, decreases expression | 4 |
| sodium arsenite | increases expression, decreases expression, affects cotreatment, increases abundance | 3 |
| Cyclosporine | decreases expression | 3 |
| Benzo(a)pyrene | decreases expression | 2 |
| Nickel | decreases expression | 2 |
| Ozone | affects expression, increases abundance, increases expression | 2 |
| sotorasib | affects cotreatment, increases expression | 1 |
| methylmercuric chloride | decreases expression | 1 |
| pirinixic acid | increases activity, affects binding, decreases expression | 1 |
| bisphenol A | affects expression | 1 |
| beta-lapachone | decreases expression | 1 |
| arsenite | affects binding, increases reaction | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | decreases expression | 1 |
| cobaltous chloride | decreases expression | 1 |
| manganese chloride | affects cotreatment, decreases expression, increases abundance | 1 |
| periodate-oxidized adenosine | affects expression | 1 |
| perfluoro-n-nonanoic acid | decreases expression | 1 |
| K 7174 | decreases expression | 1 |
| erucylphospho-N,N,N-trimethylpropylammonium | decreases expression | 1 |
| trametinib | affects cotreatment, increases expression | 1 |
| (+)-JQ1 compound | decreases expression | 1 |
| MT19c compound | decreases expression | 1 |
| NVP-BKM120 | affects cotreatment, increases expression | 1 |
| Temozolomide | increases expression | 1 |
| Arsenic Trioxide | increases expression | 1 |
| Acetaminophen | decreases expression | 1 |
| Air Pollutants | increases abundance, affects expression | 1 |
| Arsenic | affects cotreatment, decreases expression, increases abundance | 1 |
| Cisplatin | increases expression | 1 |
| Hydrogen Peroxide | affects expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.